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INTRODUCTION
Locally advanced or metastatic basal cell carci-
noma (BCC) has traditionally been difficult to treat.
Options for unresectable tumors have been limited
to cisplatin-based chemotherapy or palliative radi-
ation therapy. With the advent of molecularly
targeted drugs to the hedgehog (Hh) pathway,
another option is now available. In some cases,
these new drugs have already provided patients
with significant increases in overall survival
rates.1,2
Vismodegib was the first drug within this group
to be commercially available in January of 2012. It
inhibits a transmembrane protein known as smooth-
ened (SMO),3 which in turn down regulates the
expression of Gli genes that are responsible for
promoting tumorigenesis.4 Sonidegib, which tar-
gets the same SMO protein, was the second to be
approved by the US Food and Drug Administration
(FDA) for patients in 2015. In addition to these
newly approved drugs, itraconazole, an older anti-
fungal medication, has recently been identified as
an inhibitor of the same pathway, albeit through a
different mechanism, to reduce BCC tumor load in
humans.5
Here we present a case of a patient with locally
advanced BCC of the ethmoid sinus and brain who
subsequently had resistance to vismodegib but then
responded to a second round of combination treat-
ment using sonidegib and itraconazole.
CASE REPORT
An 87-year-old white man presented to our clinic
with an inoperable advanced BCC involving the
sinuses and brain. Five years earlier, he was placed
on vismodegib through a clinical trial for the same
tumor, which at that time only involved the nasal
cavity and sinuses. He responded dramatically to
treatment with approximately 70% reduction in
tumor size within the first 3 months. Treatment was
continued for more than a year, but effects dimin-
ished over time, and because of the negative side
effects of therapy, vismodegib was discontinued.
The patient was then treated with electron beam
radiation therapy with a total dose of 70 Gy.
Two years later, the BCC recurred, occupying the
left nasal cavity, ethmoid sinus, and frontal sinus
and extending into the left orbit. The patient was
placed back on vismodegib for 6 months; however,
the tumor continued to progress. Radiation therapy
was not an option because of cumulative dose
limitations to critical structures. Because the patient
did not respond to an inhibitor of the Hh pathway,
he was placed on a new medication with a different
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mechanism of action, pembrolizumab. After 3
cycles, a positron emission tomography scan
showed further progression of the tumor with a
new lesion identified in the right frontal lobe of the
brain that was approximately 2 cm in size. Given
tumor invasion into the brain, and inability to treat
with further radiation therapy, hospice was dis-
cussed and offered.
The patient was interested in pursuing further
medical options. Thus, he was started on 2 different
Hh pathway inhibitors at the same time, sonidegib
and itraconazole. Sonidegib was given as a daily
dose of 200 mg. Because there was a concern for
drug-drug interaction, itraconazole was pulse
dosed at 100 mg/d for 2 weeks followed by a rest
period for 2 weeks. This regimen for itraconazole
was repeated every month. The patient was
monitored with blood work and experienced no
major adverse side effects.
After 3 months, there was a significant improve-
ment shown by magnetic resonance imaging (Fig 1).
The frontal lobe tumor regressed while the tumor in
the sinus stabilized. After approximately 8 months
of treatment, the intracranial lesion, which initially
measured 1.8 3 1.3 3 1.9 cm and was T2 hyperin-
tense, was now no longer visible on the T2-weighted
sequences, and the intranasal and sinus lesions were
largely stable to slightly improved.
DISCUSSION
This report provides evidence that patients with
advanced or metastatic BCC who initially do not
respond to an Hh pathway inhibitor may benefit
from other drugs within the same class. Often in
therapy, the decision is made to try a different drug
class after one fails. Our patient was given
pembrolizumab after not responding to an
Hh inhibitor. Pembrolizumab is a humanized
monoclonal antibody that attaches and binds the
programmed cell death protein 1 receptor on
lymphocytes and blocks immune suppression by
the tumor. It has been dramatically effective in some
metastatic melanomas,6 but in this case was
ineffective in halting the growth of this patient’s
advanced BCC. We returned to targeting the Hh
pathway because it initially showed response but
this time used drugs with alternate targets. Although
vismodegib, sonidegib, and itraconazole all act to
inhibit the action of the SMO protein, their
mechanisms of action are slightly different.
Vismodegib and sonidegib are distinct molecules
and thought to act at different binding sites on the
SMO protein. In addition, different amino acid
mutations on the SMO protein are required to confer
resistance to either vismodegib7 or sonidegib,8 also
suggesting that they act at different binding sites.
Fig 1. Magnetic resonance imaging of advanced BCC of the frontal lobe during treatment with
sonidegib and itraconazole. T2-weighted axial (A) or sagittal (B) images of the brain, face, and
orbits show regression of the intracranial lesion over time. Arrow indicates the lesion within the
frontal lobe.
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Itraconazole is believed to inhibit the Hh by
preventing the transport of the SMO protein to the
cilia, a mechanism known as cilial transportation
inhibition.9 Future patients with advanced BCC who
become refractory to one Hh therapy should be
considered candidates for other drugs within this
same pathway.
Combination therapy is not a new concept in
medicine. This approach has been used successfully
in the treatment of infectious disease, as in HIV, and
traditional chemotherapy in oncology. By targeting
multiple sites within the same pathway, the hope is
that the desired effect is synergistic, and there is less
chance of resistance. This is particularly important
in cancer therapy, in which genetic and protein
mutations can result in escape from drug
effectiveness. Advanced BCC is no different than
other cancers. Reports have already identified
multiple mutations in amino acids within the SMO
protein that are responsible for resistance to
both vismodegib and sonidegib.7,8 Given this
observation, multiple drug therapy may be a more
ideal approach for the Hh pathway. A longer-term
follow-up of this patient as well as future studies
may help determine if using more than one drug at a
time will provide a longer-lasting response.
This patient is advanced in age with borderline
kidney function, and there was some initial concern
about placing him on both sonidegib and
itraconazole. Itraconazole is a strong inhibitor of
the cytochrome P-450 CYP3A pathway in the liver.
Sonidegib is metabolized through the same system.10
We, therefore, pulsed itraconazole with a low dose of
100 mg/d, 2 weeks on and 2 weeks off. The patient
tolerated this regimen well with minimal side effects.
Further experimentation will determine optimal
dosing combinations in the future.
Our patient had a positive response using both
itraconazole and sonidegib for advanced BCC after
failure of vismodegib. This observation supports that
combination therapy to inhibit the Hh pathway can
be well tolerated, the use of itraconazole and/or
sonidegib may be an option in the treatment of BCC
extension within the brain, and alternative Hh
inhibitors may produce a positive response even
when another has failed.
The authors thank Drs Clark C. Otley, Tri H. Nguyen,
and Michael R. Migden for review, discussion, and insights
with this case.
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